Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, January 25, 2023
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Tue, January 24, 2023
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Matthew Harrison Maintained (VRTX) at Hold with Increased Target to $286 on, Jan 24th, 2023
Matthew Harrison of Morgan Stanley, Maintained "Vertex Pharmaceuticals Incorporated" (VRTX) at Hold with Increased Target from $285 to $286 on, Jan 24th, 2023.
Matthew has made no other calls on VRTX in the last 4 months.
There are 15 other peers that have a rating on VRTX. Out of the 15 peers that are also analyzing VRTX, 6 agree with Matthew's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Do Kim of "Piper Sandler" Maintained at Hold with Increased Target to $296 on, Thursday, January 19th, 2023
- Whitney Ijem of "Canaccord Genuity" Initiated at Hold and Held Target at $311 on, Wednesday, January 18th, 2023
- Michael Yee of "Jefferies" Downgraded from Strong Buy to Hold and Held Target at $340 on, Monday, December 19th, 2022
- Brian Abrahams of "RBC Capital" Maintained at Hold and Held Target at $301 on, Tuesday, November 15th, 2022
- Brian Skorney of "Baird" Maintained at Hold and Held Target at $280 on, Monday, October 31st, 2022
- Paul Matteis of "Stifel" Maintained at Hold and Held Target at $289 on, Sunday, October 30th, 2022
These are the ratings of the 9 analyists that currently disagree with Matthew
- David Risinger of "SVB Leerink" Upgraded from Hold to Buy and Increased Target to $374 on, Tuesday, January 17th, 2023
- Jasper Hellweg of "Argus Research" Maintained at Strong Buy with Increased Target to $340 on, Thursday, November 17th, 2022
- Hartaj Singh of "Oppenheimer" Maintained at Buy and Held Target at $350 on, Friday, November 11th, 2022
- Salveen Richter of "Goldman Sachs" Maintained at Strong Buy with Increased Target to $442 on, Monday, October 31st, 2022
- Phil Nadeau of "TD Cowen" Maintained at Buy with Increased Target to $330 on, Friday, October 28th, 2022
- Mohit Bansal of "Wells Fargo" Maintained at Buy with Increased Target to $335 on, Friday, October 28th, 2022
- Gena Wang of "Barclays" Maintained at Buy with Increased Target to $313 on, Friday, October 28th, 2022
- Jessica Fye of "JP Morgan" Maintained at Buy with Increased Target to $327 on, Monday, October 24th, 2022
- Colin Bristow of "UBS" Maintained at Strong Buy with Increased Target to $337 on, Friday, October 21st, 2022
